Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer
1998

Radiotherapy for Advanced Non-Small-Cell Lung Cancer

Sample size: 1629 publication Evidence: moderate

Author Information

Author(s): JM Singer, P Price, RG Dale

Primary Institution: Hammersmith Hospital, Imperial College School of Medicine

Hypothesis

What is the optimal radiotherapy dose schedule for advanced non-small-cell lung cancer?

Conclusion

Higher radiation doses may improve local control and survival but can increase normal tissue toxicity.

Supporting Evidence

  • Patients treated with higher doses had better local control and survival.
  • Single fraction of 10 Gy was effective for symptom control with less toxicity.
  • Radiotherapy regimens varied significantly between North America and the UK.

Takeaway

Doctors are trying to find the best way to use radiation to help lung cancer patients feel better and live longer, but using too much radiation can also hurt healthy parts of the body.

Methodology

The study analyzed data from four randomized phase III trials in the UK and one in the USA, comparing various radiotherapy regimens.

Limitations

The study's conclusions may not apply to patients receiving chemotherapy or those with metastatic disease.

Participant Demographics

Patients with advanced non-small-cell lung cancer, including those with varying performance statuses.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication